Immunonkologische Therapie vs. Chemotherapie – aktuelle Konzepte bei Hals-Kopf-Tumoren

Die Systemtherapie des rezidivierten/metastasierten Plattenepithelkarzinoms des Kopf-Halses (R/M-SCCHN) ist auf dem Weg in eine neue Epoche. Die platinbasierte Chemotherapie stellte bislang den unangefochtenen Goldstandard dar; zukünftige Therapiekonzepte könnten jedoch durch den weiteren Siegeszug der Checkpoint-Inhibitoren (CPI) geprägt sein. Dieser Beitrag skizziert die wesentlichen Therapieoptionen und mögliche relevante Perspektiven der CPI.

• Literatur

• 1 Vermorken JB, Mesia R, Rivera F. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. New Engl J Med 2008; 359: 1116-1127
• 2 Mesía R, Rivera F, Kawecki A. et al. Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 2010; 21: 1967-1973
• 3 Argiris A, Harrington KJ, Tahara M. et al. Evidence-based treatment options in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Front Oncol 2017; 7: 72
• 4 Guigay J, Fayette J, Dillies AF. et al. Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study. Ann Oncol 2015; 26: 1941-1947
• 5 Gillison ML, Blumenschein G, Fayette J. et al. CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. Oncologist 2017; 23: 1079-1082
• 6 Stewart JSW, Cohen EEW, Licitra L. et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck corrected. J Clin Oncol 2009; 27: 1864-1871
• 7 Ferris R, Gillison ML. Nivolumab for Squamous-Cell Cancer of Head and Neck. N Engl J Med 2017; 376: 596
• 8 Cohen EEW, Soulières D, Le TourneauC. et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 2018;
• 9 Siu LL, Even C, Mesía R. et al. Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial. JAMA Oncol 2018;
• 10 Burtness B, Harrington KJ, Greil R. et al. KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Annals Oncol 2018; 29: mdy424. 045